EGFR G719S

虽然不像L858R突变那样反复出现，但EGFR G719S也被证明是一种激活突变。在肺癌细胞系中，它也对酪氨酸激酶抑制剂吉非替尼和厄洛替尼具有敏感性。
While not as recurrent as the L858R mutation, EGFR G719S has also been shown to be an activating mutation. In lung cancer cell lines, it also confers sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib.